Halozyme Therapeutics reported $152.36M in Sales Revenues for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
DBV Technologies DBVT:US 1.53M 1.02M
Acadia Pharmaceuticals ACAD:US $ 134.56M 19.1M
Agios Pharmaceuticals AGIO:US $ 5.58M 4.75M
Alnylam Pharmaceuticals ALNY:US $ 224.82M 11.56M
Amarin AMRN:US $ 94.44M 0.19M
Amgen AMGN:US $ 6594M 356M
Baxter International BAX:US $ 3746M 39M
Cara Therapeutics CARA:US $ 23M 18.21M
Cytokinetics CYTK:US $ 88.97M 87.82M
Eli Lilly And LLY:US $ 6488M 1322M
Esperion Therapeutics ESPR:US $ 18.84M 5K
Halozyme Therapeutics HALO:US $ 152.36M 35.09M
Immunogen IMGN:US $ 14.16M 23.92M
Intercept Pharmaceuticals ICPT:US $ 71.76M 16.82M
Intra Cellular Therapies ITCI:US $ 55.58M 20.58M
Intrexon XON:US $ 2.91M 29.11M
JAZZ PHA JAZZ:US $ 932.88M 119.16M
Mannkind MNKD:US $ 18.89M 6.9M
Nektar Therapeutics NKTR:US $ 21.58M 3.24M
Peregrine Pharmaceuticals PPHM:US $ 36.69M 5.47M
Pfizer PFE:US $ 27742M 2081M
Rigel Pharmaceuticals RIGL:US $ 29.82M 13.08M
United Therapeutics UTHR:US $ 466.9M 5M
Vanda Pharmaceuticals VNDA:US $ 128.78M 68.59M